DexCom (NASDAQ:DXCM) Posts Earnings Results, Beats Expectations By $0.09 EPS

DexCom (NASDAQ:DXCM) posted its quarterly earnings data on Thursday. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09, Zacks reports. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.32 earnings per share.

Here are the key takeaways from DexCom’s conference call:

• Company reported Q1 revenue of $1.19 billion (up 15% YoY, organic +12%), with gross margin improving to 63.5%, operating income and adjusted EBITDA up materially, and management reaffirmed FY revenue guidance while raising operating profit and EBITDA margin guidance.
• Product momentum from the G7 15‑Day rollout was strong — customers praised the longer wear and improved algorithm (company estimates ~50% of base will convert by year‑end) — and Dexcom is deploying adhesive and software (Stelo redesign, Smart Basal pilot) updates to further drive adoption and retention.
• Payer access is expanding — Prime Therapeutics will cover Dexcom CGM for commercial type‑2 non‑insulin patients this summer, putting coverage at >7 million non‑insulin lives by year‑end, and a randomized control trial readout at ADA 2026 is expected to support broader reimbursement efforts.
• Management reiterated gross margin guidance but flagged a 50–100 bps potential headwind from geopolitical/fuel and resin price uncertainty, leaving timing for broader CMS coverage for type‑2 non‑insulin patients still uncertain.
• Cash generation was strong — ending the quarter with ~$2.4 billion in cash and significant free cash flow — giving flexibility for capital allocation (buybacks, tuck‑ins, manufacturing investments) that management plans to discuss at Investor Day.

DexCom Price Performance

NASDAQ DXCM traded up $1.80 on Friday, reaching $61.35. 10,561,272 shares of the stock traded hands, compared to its average volume of 4,931,468. The firm’s fifty day simple moving average is $65.87 and its 200 day simple moving average is $66.40. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. The company has a market cap of $23.67 billion, a price-to-earnings ratio of 29.21, a P/E/G ratio of 1.12 and a beta of 1.55. DexCom has a 12 month low of $54.11 and a 12 month high of $89.98.

DexCom News Summary

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q1 beat on both EPS and revenue — DexCom reported $0.56 non-GAAP EPS vs. ~$0.47 consensus and revenue of $1.19B (≈+15% YoY), with margins improving. That fundamental beat and margin expansion are the main drivers supporting the stock’s upside today. Zacks: DXCM Stock Up on Q1 Earnings
• Positive Sentiment: International strength and product launches helped revenue growth — management highlighted strong demand outside the U.S. and strategic launches that supported the quarter, suggesting durable end-market demand for CGMs. Yahoo: Q1 Highlights
• Positive Sentiment: Analyst support remains — BTIG reaffirmed a Buy rating (trimmed PT to $80 from $85) and brokers’ consensus PT sits around $86.50, which provides near-term analyst backing for the shares. Yahoo: BTIG Remains Bullish
• Neutral Sentiment: Earnings call materials and transcripts available — Management detailed results and strategy on the Q1 call; slide deck and full transcripts provide more color for investors to parse guidance assumptions and regional dynamics. Seeking Alpha: Q1 Presentation
• Neutral Sentiment: Consensus price targets and coverage — Broker consensus and note flow (including an $86.50 consensus PT) give a reference for upside vs. current valuation, but don’t change near-term fundamentals. American Banking News: Consensus PT
• Negative Sentiment: Management maintained (did not raise) FY26 revenue outlook due to geopolitical uncertainty — although the company reiterated its full-year forecast (~$5.2–$5.3B), investors reacted negatively to the lack of an upward guide and the revenue range being close to Street estimates, which pressured shares after hours in prior trading. Medical Device Network: Maintains FY26 Outlook
• Negative Sentiment: After-hours weakness earlier — media reports noted an after-hours dip despite the beat, reflecting investor sensitivity to guidance commentary and expectations for a stronger raise. That earlier volatility explains mixed intraday moves around the beat. Investing.com: After-hours Reaction

Analyst Ratings Changes

A number of research firms have weighed in on DXCM. Raymond James Financial set a $81.00 price objective on shares of DexCom in a research report on Friday. Piper Sandler reiterated an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Evercore raised DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective for the company in a report on Tuesday, March 24th. Wells Fargo & Company lowered their price objective on DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a report on Friday, February 13th. Finally, BTIG Research reissued a “buy” rating and issued a $85.00 price objective on shares of DexCom in a report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $83.73.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the sale, the executive vice president directly owned 111,204 shares in the company, valued at $7,010,300.16. The trade was a 1.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.32% of the stock is owned by insiders.

Institutional Investors Weigh In On DexCom

Several large investors have recently modified their holdings of the stock. DV Equities LLC acquired a new stake in DexCom during the 4th quarter worth about $36,000. Aster Capital Management DIFC Ltd acquired a new stake in DexCom during the 4th quarter worth about $63,000. Quarry LP acquired a new stake in DexCom during the 3rd quarter worth about $72,000. Summit Securities Group LLC raised its holdings in DexCom by 817.2% during the 4th quarter. Summit Securities Group LLC now owns 1,174 shares of the medical device company’s stock worth $78,000 after buying an additional 1,046 shares during the period. Finally, Palisade Asset Management LLC acquired a new stake in DexCom during the 3rd quarter worth about $81,000. 97.75% of the stock is owned by institutional investors.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.